It looks like you’re referring to NCT04512345 and tinidazole, possibly in the context of cancer research. Here’s the key point:
Tinidazole and cancer (NCT04512345)
Tinidazole is an antibiotic/antiprotozoal (a nitroimidazole). In cancer, nitroimidazoles are often studied because they can sensitize tumors to radiation/chemotherapy by targeting hypoxic (low-oxygen) tumor regions—which are typically more resistant to treatment.
However, I can’t reliably confirm from just the fragment “NCT04512345 tinidazole cancer” what that specific trial’s exact details are (drug, cancer type, phase, sponsor, endpoints) without pulling the record.
What I need from you
Could you paste one of the following so I can answer precisely?
- the trial title (or a snippet from the ClinicalTrials.gov page), or
- the cancer type being studied, or
- the study phase and any listed study drugs, or
- a link to the NCT04512345 page.
Meanwhile: what to expect in tinidazole cancer trials
Common study designs include:
- Tinidazole + standard therapy (often radiation ± chemo)
- Measuring outcomes like tumor response, progression-free survival, or safety/tolerability
- Biomarker interest in hypoxia or related oxygenation effects
Important safety note
Tinidazole can cause side effects (e.g., nausea, metallic taste, headaches) and has interaction warnings (notably with alcohol; and certain drug interactions depending on regimen). If this is about participation, it’s important to review eligibility and interaction lists with the trial team.
If you share the ClinicalTrials.gov title/snippet, I’ll tell you exactly what NCT04512345 is studying—which cancer, the dosing/regimen, phase, and what the primary outcomes are.